|
31 Jul 2025 |
Dr. Reddy's Labs
|
Consensus Share Price Target
|
1292.10 |
1284.09 |
- |
-0.62 |
hold
|
|
|
|
|
30 Oct 2023
|
Dr. Reddy's Labs
|
Axis Direct
|
1292.10
|
5850.00
|
5345.35
(-75.83%)
|
Target met |
Hold
|
|
|
We believe the company's strategy of investing in various businesses may provide growth in the long term
|
|
30 Oct 2023
|
Dr. Reddy's Labs
|
BOB Capital Markets Ltd.
|
1292.10
|
5500.00
|
5345.35
(-75.83%)
|
Target met |
Hold
|
|
|
Q2 revenue in line but PAT outdid consensus by 22% on account of PLI benefits, litigation settlement and interest income
|
|
29 Oct 2023
|
Dr. Reddy's Labs
|
Prabhudas Lilladhar
|
1292.10
|
5300.00
|
5397.30
(-76.06%)
|
Target met |
Sell
|
|
|
|
|
28 Oct 2023
|
Dr. Reddy's Labs
|
ICICI Securities Limited
|
1292.10
|
6000.00
|
5397.30
(-76.06%)
|
Target met |
Accumulate
|
|
|
Dr. Reddy’s Laboratories’ (DRL) Q2FY24 gross and EBITDA margins were down 198bps/273bps YoY to 58.7%/28.9%, respectively. US price erosion, acquisition of Mayne Pharma and higher SG&A investments dented margins.
|
|
28 Oct 2023
|
Dr. Reddy's Labs
|
Motilal Oswal
|
1292.10
|
5400.00
|
5397.30
(-76.06%)
|
Target met |
Neutral
|
|
|
|
|
24 Aug 2023
|
Dr. Reddy's Labs
|
Geojit BNP Paribas
|
1292.10
|
6212.00
|
5907.15
(-78.13%)
|
Target met |
Hold
|
|
|
|
|
27 Jul 2023
|
Dr. Reddy's Labs
|
Motilal Oswal
|
1292.10
|
5240.00
|
5507.00
(-76.54%)
|
Target met |
Neutral
|
|
|
|
|
27 Jul 2023
|
Dr. Reddy's Labs
|
SMC online
|
1292.10
|
|
5507.00
(-76.54%)
|
Pre-Bonus/ Split |
Results Update
|
|
|
|
|
27 Jul 2023
|
Dr. Reddy's Labs
|
Axis Direct
|
1292.10
|
6000.00
|
5507.00
(-76.54%)
|
Target met |
Hold
|
|
|
We have HOLD on the stock
|
|
27 Jul 2023
|
Dr. Reddy's Labs
|
ICICI Securities Limited
|
1292.10
|
6000.00
|
5475.65
(-76.40%)
|
Target met |
Accumulate
|
|
|
Dr. Reddy’s (DRL) delivered a strong beat in EBITDA and profit, driven by incremental sales from its base product portfolio and gRevlimid in the US. gRevlimid continues to lift overall margins; however, additional sales from products that are in shortage in the US improved base business margins in Q1FY24.
|